Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases-Reference-Cited by-同舟云学术

Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases

Published:2024-02-13 Issue:4 Volume:67 Page:2397-2424
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lescop Cyrille¹,Birker Magdalena²,Brotschi Christine¹,Bürki Cédric³^ORCID,Morrison Keith⁴,Froidevaux Sylvie⁴,Delahaye Stéphane⁵,Nayler Oliver²,Bolli Martin H.¹^ORCID

Affiliation:

1. DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland

2. DD Biology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland

3. Chemistry Process R&D, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland

4. DD Pharmacology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland

5. Preclinical DMPK, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01827

Reference59 articles.

1. Two pathways for lysophosphatidic acid production

2. Lysophosphatidic acid (LPA) receptor modulators: Structural features and recent development

3. Molecular mechanisms of lysophosphatidic acid action

4. Aiming drug discovery at lysophosphatidic acid targets

5. The LPA receptors

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold;Journal of Medicinal Chemistry;2024-02-13